No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AZTA240621C50000
- 2.80
- 0.000.00%
15min DelayTrading Jun 18 16:00 ET
0.00High0.00Low
0.00Open2.80Pre Close0 Volume1 Open Interest50.00Strike Price0.00Turnover109.85%IV-5.76%PremiumJun 21, 2024Expiry Date6.03Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9196Delta0.0366Gamma20.01Leverage Ratio-0.1477Theta0.0020Rho18.40Eff Leverage0.0055Vega
Intraday
- 5D
- Daily
No Data
News
Azenta Insiders Sold US$1.6m Of Shares Suggesting Hesitancy
In the last year, many Azenta, Inc. (NASDAQ:AZTA) insiders sold a substantial stake in the company which may have sparked shareholders' attention. When analyzing insider transactions, it is usually
Azenta Announces Collaboration With the Crohn's & Colitis Foundation to Support Its Crohn's Disease and Ulcerative Colitis Clinical Research
Azenta has been Selected by the Crohn's & Colitis Foundation as its Sample Management Services Provider for its Inflammatory Bowel Disease (IBD) CAPTURE and SIRQC Clinical Registries BURLINGTON, Mass
Azenta to Participate in the Jefferies Global Healthcare Conference
BURLINGTON, Mass., May 23, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the Jefferies Global Healthcare Conference in New York, NY, on
Azenta Opens the Doors to Its New Genomics Laboratory in Oxford, UK
Azenta, Inc. (Nasdaq: AZTA) today announced the grand opening of the new Genomics Laboratory in Oxford, UK, expanding its global reach of GENEWIZ...
Azenta Inc (AZTA) Q2 Fiscal 2024 Earnings: Revenue Growth Amid Challenges
The Analyst Landscape: 7 Takes On Azenta
Across the recent three months, 7 analysts have shared their insights on Azenta (NASDAQ:AZTA), expressing a variety of opinions spanning from bullish to bearish.The following table encapsulates their
Comments
Insider selling at Azenta, even at a lower share price, implies they considered it reasonable. Despite some alignment with common shareholders, the lack of insider buying over the past year is discouraging.
Azenta Insiders Sold US$1.7m Of Shares Suggesting HesitancyThe elevated P/S ratio of Azenta shows the market's faith in its capacity to weather global industry headwinds. This is why Azenta's P/S ratio outpaces most other firms. Shareholder sentiment may remain steady barring any shift in these circumstances.
Azenta stock may not be an optimal investment now considering the negative growth outlook and fair valuation. Its high beta could offer future trades if market conditions change.
The large sales by insiders, even at a price below the current rate, are seen as a potentially discouraging sign. However, insiders owning a reasonable chunk of the company indicates an alignment of interests with other shareholders.
Despite Azenta's falling revenues and non-profitability, the stock has delivered respectable returns. The link between past revenue performance and share price remains murky. A recent uptick in one-year TSR Vs five-year TSR suggests potentially growing business momentum.
Read more